School of Biotechnology, KIIT University, Bhubaneswar, India.
Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia.
Front Immunol. 2018 Oct 4;9:2224. doi: 10.3389/fimmu.2018.02224. eCollection 2018.
Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.
由于致病微生物新变体的出现,传染病的治疗和免疫接种在过去几年中成为了巨大的挑战。在疫苗开发方面,人们做出了巨大努力来开发新疫苗,并提高针对特定疾病的现有疫苗的功效。迄今为止,一些疫苗是由蛋白质亚单位或已杀死的病原体开发的,而有几种疫苗则基于减毒活生物体,这些生物体在某些免疫功能低下的情况下有恢复其致病性的风险。为了避免这种情况,开发无风险的有效疫苗并结合适当的输送系统被认为是获得针对传染病所需的体液和细胞介导免疫的必要条件。在过去的几年中,基于纳米颗粒的疫苗的使用受到了极大的关注,以提高疫苗的功效、免疫策略和靶向递送,以在细胞水平上实现所需的免疫反应。为了提高疫苗的功效,这些纳米载体应保护抗原免受过早的蛋白水解降解,促进抗原呈递细胞摄取和处理抗原,控制释放,并且对人体使用安全。由脂质、蛋白质、金属或聚合物组成的纳米载体已经被用于实现其中的一些特性。在这方面,纳米颗粒的一些物理化学性质在确定疫苗功效方面起着重要作用。本文重点介绍了基于纳米载体的疫苗制剂的应用,以及用于纳米颗粒功能化的策略,以实现疫苗的有效递送来诱导针对传染病的所需宿主免疫。
Front Immunol. 2018-10-4
Expert Opin Drug Deliv. 2021-2
Nanomedicine (Lond). 2017-5
Recent Pat Drug Deliv Formul. 2007
Front Cell Infect Microbiol. 2013-3-25
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021-5
Biochem Pharmacol. 2016-11-15
Curr Drug Deliv. 2011-5
Pharm Nanotechnol. 2020
Pharmaceutics. 2025-7-25
Int J Mol Sci. 2025-7-22
Biomater Transl. 2025-3-25
Front Immunol. 2018-2-28
Pharmaceutics. 2017-11-20
Nanomedicine (Lond). 2016-11-23
J Pharm Pharm Sci. 2016